201. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N
Eng J Med 1991; 325: 1468-1475.
202. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
Vesnarinone Trial Investigators. N Eng J Med 1998; 339: 1810-1816.
203. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart
and vessels 1994; 9: 113-120.
204. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in
Congestive Heart Failure (PICO) trial. Heart (British Cardiac Society) 1996; 76: 223-231.
205. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan
on chronic heart failure study (EPOCH study). Circ J 2002; 66: 149-157.
206. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up
Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 2008; 1: 9-16.
207. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind,
placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
208. Lenihan DJ, Gerson MC, Hoit BD, et al. Mechanisms, diagnosis, and treatment of diastolic heart failure. Am Heart J 1995; 130: 153-166.
209. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
Circulation 1984; 70: 1030-1037.
210. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. American
journal of hypertension 1992; 5: 95-110.
211. Carson P, Johnson G, Fletcher R, et al. Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics,
prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 1996; 27: 642-649.
212. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the
CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
213. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
214. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Eng J Med 2008; 359: 2456-2467.
215. Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-192.
216. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Betablockade with nebivolol in elderly heart failure patients with impaired and preserved left
ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart
Failure). J Am Coll Cardiol 2009; 53: 2150-2158.
217. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the
American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for
Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration
with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
218. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714.
219. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of
Antiarrhythmic Therapy in Congestive Heart Failure. N Eng J Med 1995; 333: 77-82.
220. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent
myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.
221. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990; 65: 42I-8I.
222. Bourke JP, Cowan JC, Tansuphaswadikul S, et al. Antiarrhythmic drug effects on left ventricular performance. Eur Heart J 1987; 8 Suppl A: 105-111.
223. Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic
treatment. BMJ (Clinical research ed.) 2000; 320: 495-498.
224. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm.
The American journal of medicine 1988; 85: 242-244.
225. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated
cardiomyopathy. Am J Cardiol 1992; 69: 1570-1573.
226. Fresco C, Proclemer A. Clinical challenge. II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators. Eur Heart J 1996; 17 Suppl. C: 41-48.
227. Deedwania PC, Singh BN, El lenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure
and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHFSTAT). The Department
of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574-2579.
228. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of
randomized control trials. Circulation 1990; 82: 1106-1116.
229. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial
Fibrillation Investigators. J Am Coll Cardiol 1992; 20: 527-532.
230. Shiga T, Wakaumi M, Imai T, et al. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 2002; 66:
600-604.
231. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Eng J Med 2008; 358: 2667-2677.
232. Goldman S, Johnson G, Cohn JN, et al. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies
Group. Circulation 1993; 87 (6 Suppl): VI24-131.
233. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac
Arrhythmia Suppression Trial (CAST) Investigators. N Eng J Med 1989; 321: 406-412.
234. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Eng J
Med 1992; 327: 227-233.
235. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of
the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/
NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American
Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: e350-408.
236. 循環器病の診断と治療に関するガイドライン．不整脈の非薬物治療ガイドライン（2006年度改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2006
_kasanuki_h.pdf（2010 年6月閲覧）．
237. Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the
American College of Cardiology/American Heart Association Task Force on Practice Guide l ine s (Committee on Clinical Intracardiac
Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology.
J Am Coll Cardiol 1995; 26: 555-573.
238. Packer DL, Bardy GH, Worley SJ, et al. Tachycardiainduced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:
563-570.
239. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from nearfatal ventricular arrhythmias. The
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Eng J Med 1997; 337: 1576-1583.
240. Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe
underlying cardiac disease. J Am Coll Cardiol 1990; 16: 381-386.
241. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital
cardiac arrest. Circulation 1993; 88: 1083-1092.
242. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct
sudden death survivors. Circulation 1995; 91: 2195-2203.
243. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular
arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Eng J Med 1996; 335: 1933-1940.
244. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter
Unsustained Tachycardia Trial Investigators. N Eng J Med 1999; 341: 1882-1890.
245. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Eng J
Med 2002; 346: 877-883.
246. Cohn JN. Current therapy of the failing heart. Circulation 1988; 78 (5 Pt 1): 1099-1107.
247. Shiba N, Watanabe J, Shinozaki T, et al. Analysis of chronic heart failure registry in the Tohoku district: third year followup. Circ J 2004; 68: 427-434.
248. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ
J 2007; 71: 449-454.
249. SHEPCooperativeStudyGroup. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results
of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-3264.
250. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
251. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
252. 日本高血圧学会．高血圧治療ガイドライン 2009．ライフサイエンス出版 2009.
253. Shiba N, Watanabe J, Shinozaki T, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--comparison
with nonischemic cardiomyopathy. Circ J 2005; 69: 143-149.
254. Elefteriades JA, Tolis G, Jr., Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection
fraction and functional state. J Am Coll Cardiol 1993; 22: 1411-1417.
255. Baker DW, Jones R, Hodges J, et al. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe
left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534.
256. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N
Eng J Med 1985; 312: 1665-1671.
257. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACPASIM guidelines for the management of patients with chronic stable angina: a report of the
American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic
Stable Angina). J Am Coll Cardiol 1999; 33: 2092-2197.
258. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects.
Am J Cardiol 2004; 93: 969-973.
259. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart
failure treated with angiotensinconverting enzyme inhibition. Circulation 1999; 99: 2652-2657.
260. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans
Administration Cooperative Study. N Eng J Med 1986; 314: 1547-1552.
261. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine
therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-1961.
262. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Eng
J Med 1988; 319: 385-392.
263. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients
with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;
27: 181-191.
264. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in
patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
265. Kitakaze M, Asanuma H, Funaya H, et al. Angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers synergistically increase
coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 2002; 40: 162-166.
266. Kawashiro N, Kasanuki H, Ogawa H, et al. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the
HIJC-HF registry. Circ J 2008; 72: 2015-2020.
267. 伊藤貞嘉．心臓と腎臓の機能役割．In: 松崎益德，伊藤貞嘉，editor．心腎連関を識る．東京，分光堂 2008: 2-11.
268. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe,
resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll
Cardiol 2000; 35: 1737-1744.
269. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl. 1):
S1-266.
270. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the
American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology
and Prevention. Hypertension 2003; 42: 1050-1065.
271. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
272. Adams KF, Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale,
design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart
J 2005; 149: 209-216.
273. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients
hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73:
1442-1447.
274. Shiba N, Matsuki M, Takahashi J, et al. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J 2008;
72: 173-178.
275. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-1764.
276. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-513.
277. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney
disease and proteinuria: a metaanalysis. Am Heart J 2008; 155: 791-805.
278. Saltzman HE, Sharma K, Mather PJ, et al. Renal dysfunction in heart failure patients: what is the evidence? Heart failure reviews 2007; 12: 37-47.
279. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart
failure and chronic kidney disease. Am Heart J 2007; 153: 1064-1073.
280. Abbott KC, Trespalacios FC, Agodoa LY, et al. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and
mortality. Archives of internal medicine 2004; 164: 2465-2471.
281. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-
controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
282. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease:
a randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512.
283. Shlipak MG, Smith GL, Rathore SS, et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group
trial. J Am Soc Nephrol. 2004; 15: 2195-2203.
284. Choy CK, Rodgers JE, Nappi JM, et al. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28: 170-192.
285. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75.
286. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American
Heart Association and American Diabetes Association. Diabetes care 2004; 27: 256-263.
287. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular
systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.
288. Heart Failure Society Of A. Evaluation and management of patients with acute decompensated heart failure. J Card Failure 2006; 12: e86-e103.
289. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a
randomized controlled trial. JAMA 2004; 292: 2227-2236.
290. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized
with heart failure in Japan. A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-1908.
291. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol
2008; 52: 818-827.
292. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Circulation 2008; 117: 526-535.
293. van der Meer P, Groenveld HF, Januzzi JL, Jr., et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart (British
Cardiac Society) 2009; 95: 1309-1314.
294. Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences,
and presentations. Circulation 1998; 97: 2154-2159.
295. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J
Respir Crit Care Med 1999; 160: 1101-1106.
296. Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and
characteristics of 700 patients. Eur J Heart Fail 2007; 9: 251-257.
297. Chan J, Sanderson J, Chan W, et al. Prevalence of sleepdisordered breathing in diastolic heart failure. Chest 1997; 111: 1488-1493.
298. Bitter T, Faber L, Hering D, et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009; 11: 602-
608.
299. Tkacova R, Niroumand M, Lorenzi-Filho G, et al. Overnight shift from obstructive to central apneas in patients with heart failure: role of PCO2 and
circulatory delay. Circulation 2001; 103: 238-243.
300. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study.
Am J Respir Crit Care Med 2001; 163: 19-25.
Eng J Med 1991; 325: 1468-1475.
202. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
Vesnarinone Trial Investigators. N Eng J Med 1998; 339: 1810-1816.
203. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart
and vessels 1994; 9: 113-120.
204. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in
Congestive Heart Failure (PICO) trial. Heart (British Cardiac Society) 1996; 76: 223-231.
205. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan
on chronic heart failure study (EPOCH study). Circ J 2002; 66: 149-157.
206. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up
Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 2008; 1: 9-16.
207. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind,
placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
208. Lenihan DJ, Gerson MC, Hoit BD, et al. Mechanisms, diagnosis, and treatment of diastolic heart failure. Am Heart J 1995; 130: 153-166.
209. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
Circulation 1984; 70: 1030-1037.
210. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. American
journal of hypertension 1992; 5: 95-110.
211. Carson P, Johnson G, Fletcher R, et al. Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics,
prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 1996; 27: 642-649.
212. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the
CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
213. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
214. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Eng J Med 2008; 359: 2456-2467.
215. Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-192.
216. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Betablockade with nebivolol in elderly heart failure patients with impaired and preserved left
ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart
Failure). J Am Coll Cardiol 2009; 53: 2150-2158.
217. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the
American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for
Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration
with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
218. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714.
219. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of
Antiarrhythmic Therapy in Congestive Heart Failure. N Eng J Med 1995; 333: 77-82.
220. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent
myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.
221. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990; 65: 42I-8I.
222. Bourke JP, Cowan JC, Tansuphaswadikul S, et al. Antiarrhythmic drug effects on left ventricular performance. Eur Heart J 1987; 8 Suppl A: 105-111.
223. Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic
treatment. BMJ (Clinical research ed.) 2000; 320: 495-498.
224. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm.
The American journal of medicine 1988; 85: 242-244.
225. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated
cardiomyopathy. Am J Cardiol 1992; 69: 1570-1573.
226. Fresco C, Proclemer A. Clinical challenge. II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators. Eur Heart J 1996; 17 Suppl. C: 41-48.
227. Deedwania PC, Singh BN, El lenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure
and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHFSTAT). The Department
of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574-2579.
228. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of
randomized control trials. Circulation 1990; 82: 1106-1116.
229. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial
Fibrillation Investigators. J Am Coll Cardiol 1992; 20: 527-532.
230. Shiga T, Wakaumi M, Imai T, et al. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 2002; 66:
600-604.
231. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Eng J Med 2008; 358: 2667-2677.
232. Goldman S, Johnson G, Cohn JN, et al. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies
Group. Circulation 1993; 87 (6 Suppl): VI24-131.
233. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac
Arrhythmia Suppression Trial (CAST) Investigators. N Eng J Med 1989; 321: 406-412.
234. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Eng J
Med 1992; 327: 227-233.
235. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of
the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/
NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American
Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: e350-408.
236. 循環器病の診断と治療に関するガイドライン．不整脈の非薬物治療ガイドライン（2006年度改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2006
_kasanuki_h.pdf（2010 年6月閲覧）．
237. Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the
American College of Cardiology/American Heart Association Task Force on Practice Guide l ine s (Committee on Clinical Intracardiac
Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology.
J Am Coll Cardiol 1995; 26: 555-573.
238. Packer DL, Bardy GH, Worley SJ, et al. Tachycardiainduced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:
563-570.
239. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from nearfatal ventricular arrhythmias. The
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Eng J Med 1997; 337: 1576-1583.
240. Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe
underlying cardiac disease. J Am Coll Cardiol 1990; 16: 381-386.
241. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital
cardiac arrest. Circulation 1993; 88: 1083-1092.
242. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct
sudden death survivors. Circulation 1995; 91: 2195-2203.
243. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular
arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Eng J Med 1996; 335: 1933-1940.
244. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter
Unsustained Tachycardia Trial Investigators. N Eng J Med 1999; 341: 1882-1890.
245. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Eng J
Med 2002; 346: 877-883.
246. Cohn JN. Current therapy of the failing heart. Circulation 1988; 78 (5 Pt 1): 1099-1107.
247. Shiba N, Watanabe J, Shinozaki T, et al. Analysis of chronic heart failure registry in the Tohoku district: third year followup. Circ J 2004; 68: 427-434.
248. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ
J 2007; 71: 449-454.
249. SHEPCooperativeStudyGroup. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results
of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-3264.
250. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
251. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
252. 日本高血圧学会．高血圧治療ガイドライン 2009．ライフサイエンス出版 2009.
253. Shiba N, Watanabe J, Shinozaki T, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--comparison
with nonischemic cardiomyopathy. Circ J 2005; 69: 143-149.
254. Elefteriades JA, Tolis G, Jr., Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection
fraction and functional state. J Am Coll Cardiol 1993; 22: 1411-1417.
255. Baker DW, Jones R, Hodges J, et al. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe
left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534.
256. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N
Eng J Med 1985; 312: 1665-1671.
257. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACPASIM guidelines for the management of patients with chronic stable angina: a report of the
American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic
Stable Angina). J Am Coll Cardiol 1999; 33: 2092-2197.
258. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects.
Am J Cardiol 2004; 93: 969-973.
259. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart
failure treated with angiotensinconverting enzyme inhibition. Circulation 1999; 99: 2652-2657.
260. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans
Administration Cooperative Study. N Eng J Med 1986; 314: 1547-1552.
261. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine
therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-1961.
262. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Eng
J Med 1988; 319: 385-392.
263. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients
with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;
27: 181-191.
264. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in
patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
265. Kitakaze M, Asanuma H, Funaya H, et al. Angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers synergistically increase
coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 2002; 40: 162-166.
266. Kawashiro N, Kasanuki H, Ogawa H, et al. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the
HIJC-HF registry. Circ J 2008; 72: 2015-2020.
267. 伊藤貞嘉．心臓と腎臓の機能役割．In: 松崎益德，伊藤貞嘉，editor．心腎連関を識る．東京，分光堂 2008: 2-11.
268. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe,
resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll
Cardiol 2000; 35: 1737-1744.
269. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl. 1):
S1-266.
270. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the
American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology
and Prevention. Hypertension 2003; 42: 1050-1065.
271. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
272. Adams KF, Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale,
design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart
J 2005; 149: 209-216.
273. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients
hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73:
1442-1447.
274. Shiba N, Matsuki M, Takahashi J, et al. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J 2008;
72: 173-178.
275. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-1764.
276. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-513.
277. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney
disease and proteinuria: a metaanalysis. Am Heart J 2008; 155: 791-805.
278. Saltzman HE, Sharma K, Mather PJ, et al. Renal dysfunction in heart failure patients: what is the evidence? Heart failure reviews 2007; 12: 37-47.
279. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart
failure and chronic kidney disease. Am Heart J 2007; 153: 1064-1073.
280. Abbott KC, Trespalacios FC, Agodoa LY, et al. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and
mortality. Archives of internal medicine 2004; 164: 2465-2471.
281. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-
controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
282. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease:
a randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512.
283. Shlipak MG, Smith GL, Rathore SS, et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group
trial. J Am Soc Nephrol. 2004; 15: 2195-2203.
284. Choy CK, Rodgers JE, Nappi JM, et al. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28: 170-192.
285. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75.
286. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American
Heart Association and American Diabetes Association. Diabetes care 2004; 27: 256-263.
287. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular
systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.
288. Heart Failure Society Of A. Evaluation and management of patients with acute decompensated heart failure. J Card Failure 2006; 12: e86-e103.
289. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a
randomized controlled trial. JAMA 2004; 292: 2227-2236.
290. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized
with heart failure in Japan. A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-1908.
291. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol
2008; 52: 818-827.
292. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Circulation 2008; 117: 526-535.
293. van der Meer P, Groenveld HF, Januzzi JL, Jr., et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart (British
Cardiac Society) 2009; 95: 1309-1314.
294. Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences,
and presentations. Circulation 1998; 97: 2154-2159.
295. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J
Respir Crit Care Med 1999; 160: 1101-1106.
296. Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and
characteristics of 700 patients. Eur J Heart Fail 2007; 9: 251-257.
297. Chan J, Sanderson J, Chan W, et al. Prevalence of sleepdisordered breathing in diastolic heart failure. Chest 1997; 111: 1488-1493.
298. Bitter T, Faber L, Hering D, et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009; 11: 602-
608.
299. Tkacova R, Niroumand M, Lorenzi-Filho G, et al. Overnight shift from obstructive to central apneas in patients with heart failure: role of PCO2 and
circulatory delay. Circulation 2001; 103: 238-243.
300. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study.
Am J Respir Crit Care Med 2001; 163: 19-25.
文献
慢性心不全治療ガイドライン（2010年改訂版）
Guidelines for Treatment of Chronic Heart Failure（JCS 2010）
Guidelines for Treatment of Chronic Heart Failure（JCS 2010）